Bioventus Inc.
BVS
$7.51
-$0.09-1.14%
NASDAQ
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.23% | -2.35% | -4.31% | 13.45% | 15.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.23% | -2.35% | -4.31% | 13.45% | 15.04% |
| Cost of Revenue | -2.18% | -4.22% | -0.63% | 3.79% | 8.27% |
| Gross Profit | 0.72% | -1.49% | -6.02% | 18.95% | 18.64% |
| SG&A Expenses | -3.42% | -6.02% | -6.72% | 10.43% | 16.63% |
| Depreciation & Amortization | -32.30% | -30.28% | -9.23% | -15.89% | -10.88% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.04% | -6.33% | -4.29% | 7.29% | 13.37% |
| Operating Income | 81.37% | 39.27% | -4.79% | 330.66% | 67.96% |
| Income Before Tax | 188.80% | 124.82% | 37.58% | 102.76% | 35.80% |
| Income Tax Expenses | 12.73% | 114.18% | -110.47% | 173.33% | -1.83% |
| Earnings from Continuing Operations | 168.50% | 127.10% | 47.94% | 95.85% | 33.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -224.60% | -121.24% | -54.06% | -89.62% | -54.10% |
| Net Income | 161.08% | 129.04% | 46.07% | 97.44% | 29.28% |
| EBIT | 81.37% | 39.27% | -4.79% | 330.66% | 67.96% |
| EBITDA | 22.62% | 15.76% | -1.00% | 71.18% | 5.48% |
| EPS Basic | 159.54% | 127.99% | 48.32% | 97.52% | 31.93% |
| Normalized Basic EPS | 322.88% | -57.33% | 23.64% | 177.53% | 66.08% |
| EPS Diluted | 158.88% | 127.44% | 48.32% | 97.52% | 31.15% |
| Normalized Diluted EPS | 316.34% | -58.62% | 23.64% | 177.53% | 66.08% |
| Average Basic Shares Outstanding | 2.55% | 3.81% | 4.15% | 3.73% | 3.87% |
| Average Diluted Shares Outstanding | 5.48% | 6.99% | 4.15% | 3.73% | 3.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |